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Rheumatic conditions in human immunodeficiency virus infection
U. A. Walker, A. Tyndall and T. Daikeler
Many rheumatic diseases have been observed in HIV-infected persons. We, therefore, conducted a comprehensive literature search in order
to review the prevalence, presentation and pathogenesis of rheumatic manifestations in HIV-infected subjects. Articular conditions (arthralgia,
arthritis and SpAs) are either caused by the HIV infection itself, triggered by adaptive changes in the immune system, or secondary to
microbial infections. Muscular symptoms may result from rhabdomyolysis, myositis or from side-effects of highly active anti-retroviral therapy
(HAART). Osseous complications include osteonecrosis, osteoporosis and osteomyelitis. Some conditions such as the diffuse infiltrative
lymphocytosis syndrome and sarcoidosis affect multiple organ systems. SLE may be observed but may be difficult to differentiate from HIV
infection. Some anti-retroviral agents can precipitate hyperuricaemia and are associated with arthralgia. When indicated, immuno-
suppressants and even anti-TNF- agents can be used in the carefully monitored HIV patient. Thus, rheumatic diseases and asymptomatic
immune phenomena remain prevalent in HIV-infected persons even after the widespread implementation of highly active anti-retroviral
therapy.
KEY WORDS: Acquired immunodeficiency syndrome, Anti-retroviral therapy, Arthritis, Human immunodeficiency virus, Psoriasis, Rheumatic diseases,
Vasculitis.
Introduction
HIV-infected individuals are at an increased risk of developing
musculoskeletal pathology [1, 2]. Estimates of the exact prevalence
of rheumatic manifestations of HIV infection vary widely. Before
the widespread implementation of highly active anti-retroviral
therapy (HAART), retrospective studies calculated the rates of
musculoskeletal complications from 11% to 72% [3–5]. In the
HAART era, rheumatic complications declined significantly but
continue to be prevalent [6–8] with even new manifestations
emerging [9]. The aim of this article is to review the rheumatic
complications in HIV-infected subjects. An overview is provided
in Table 1.
Laboratory abnormalities
In HIV-infected patients, autoimmune phenomena may be
fostered by a polyclonal stimulation of B cells, or the homeostatic
expansion of naı¨ve and antigen-experienced T cells after the
initiation of effective HAART [10]. Laboratory abnormalities
may consist of the presence of RF, cold agglutinins or ANA [2, 5,
11–14]. Anti-centromere ANA were observed in up to 84% of
individuals and circulating immune complexes in up to 98%.
C3 and C4 complement levels were mostly normal, although in
some subjects elevated or low levels were measured [5]. ANCA
have been described at high frequency [14, 15].
Infections are a known trigger of aCL production [16]. In HIV-
infected patients, aPLs were found in up to 94% of the cases and
anti-2 glycoprotein I (GPI) antibodies in up to 47%. The lupus
anti-coagulant was mostly negative [2, 16–19]. The full picture of
the APS is uncommon [20–22], a fact which may be related to the
relatively low prevalence of anti-GPI antibodies and the observa-
tion that aCLs are often transient and disappear with anti-
retroviral treatment [16].
Arthralgia
Arthralgia is a common but unspecific complaint of HIV-infected
persons. The prevalence of arthralgia in HIV-infected persons
was 5% in retrospective and 45% in prospective studies [2, 3, 5].
Arthralgia was most frequently observed in the knees, shoulders
and elbows [5]. An intermittent painful articular syndrome has
only a short duration (a few hours), but may require opioid
analgesics [23, 24].
Arthralgia is also common in acute HIV infection. Following
an incubation period of a few days to a few weeks after HIV
infection, 40–90% of the individuals present with a flu-like illness
that includes joint pain in 28–54% of the cases. Other symptoms
are fever (80–88%), rash (51–58%), oral ulcers (8–37%), myalgias
(49–60%), pharyngitis (43%) and malaise (68–73%) [25, 26].
Fever and malaise are in fact the most sensitive symptoms for the
diagnosis of primary HIV infection but rarely persist beyond
14 days [25]. The diagnosis of acute HIV-1 infection hinges on the
presence of HIV-1 RNA in the absence of HIV-1 antibodies.
Arthritis
HIV-associated arthritis
Arthritis of different aetiology is described in 10–12% of the HIV
patients [2, 5, 27, 28]. HIV-associated arthritis can present at any
time during the course of chronic HIV infection; its prevalence
was 1% in a tertiary care setting [8]. HIV-associated arthritis
mainly manifests as a non-erosive oligoarthritis of the lower
extremities without enthesopathy, mucocutaneous involvement
and HLA-B27 gene expression [7, 27]. HIV was isolated from the
SF in only one report [29]. Most frequently, HIV-associated
arthritis is self-limited and lasts <6 weeks [27].
Reiter’s syndrome
A SpA resembling ReA is more prevalent in HIV-positive paedia-
tric and adult cohorts, compared with HIV-negative population [7].
Reiter’s syndrome was diagnosed in 0.4–10% of the HIV-infected
subjects, most of whom had asymmetric oligoarthritis [2, 5, 23, 27].
Enthesopathy is highly prevalent and sacroileitis may occur [5].
Among the extra-articular manifestations, conjunctivitis, circinate
balanitis, urethritis and keratoderma blennorrhagicum are fre-
quent [5]. HLA-B27 was positive in five of eight patients with
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HIV-associated Reiter’s syndrome [5]. SSZ has been successfully
used. Dramatic improvement with effective HIV suppression or
anti-TNF- biologics was described [30, 31].
Psoriasis and PsA
The incidence of PsA is 1.5–2% [5, 23, 27]. In general, the
severity of psoriasis parallels the impairment of the immune
system and the use of anti-retrovirals generally improves HIV-
associated psoriasis. In advanced HIV infection, psoriasis can be
generalized and extremely resistant to therapy. Anti-TNF-
agents have been successfully administered to a few patients
[32, 33], but in some cases have been associated with polymicro-
bial infections [34].
Septic arthritis
Immunodeficiency is a risk factor for septic arthritis [7, 35]; septic
tenosynovitis and bursitis have been less often described [36].
Although the joints are the most common localization of septic
complications in the musculoskeletal system [37, 38], these
infections are only observed in 1% of HIV-infected individuals
[37, 39]. The largest studies retrospectively identified 14–30 cases
of musculoskeletal infections among cohorts of 3000–4000
patients [37, 39]. There appears to be no clear association with
CD4þ counts [39]. Some studies, however, question whether HIV
infection actually predisposes for articular infections and suggest
that the predominant risk factor for septic arthritis in the HIV-
infected population is represented by simultaneous intravenous
drug abuse [39, 40].
Septic arthritis usually affects young men, with the large
weight-bearing joints of the lower extremities commonly involved
[39]. For unclear reasons, the sternoclavicular joints are a
preferred target of infection in intravenous drug users [41].
Pyogenic organisms predominate at CD4þ counts >250/l,
whereas opportunistic pathogens are observed when the CD4þ
counts are <100/l [39]. After the initiation of HAART, pre-
existing opportunistic pathogens such as mycobacteria can
become symptomatic by immune reconstitution.
Articular complications of anti-retroviral therapy
Arthralgia, monarthritis [42], oligoarthritis [43] and adhesive
capsulitis [44] have been associated specifically with the use of
indinavir. Indinavir is an anti-retroviral protease inhibitor (PI),
which tends to form drug crystals in the urogenital tract, giving
rise to nephrolithiasis. Indinavir crystals were not detected in
the SF, however [42]. Indinavir is now rarely used in HAART for
its unfavourable pharmacokinetic profile, efficacy and side-effects
[45, 46]. A prospective survey suggested that joint pain may also
be associated with other PI (ritonavir and saquinavir) [47].
Gout
High frequencies of hyperuricaemia (up to 42%) have been
observed in HIV-infected individuals [2, 48, 49]. In HIV patients,
the annual incidence of gout is 0.5%, an order of magnitude
higher than the incidence in the normal population [50–52].
With uncontrolled HIV replication, serum urate elevation may
result from increased cell turnover [49, 53]. Aside from the HIV
TABLE 1. Overview of the rheumatic manifestations in the setting of HIV infection
Manifestation Most important causes in the setting of HIV infection Principal treatment
Arthralgia Primary HIV infection Indication for temporally limited HAART controversial
Intermittent painful articular syndrome Analgesics
Indinavir, ritonavir, saquinavir Replace PI
Arthritis (see below)
Arthritis HIV-associated arthritis Symptomatic, consider indomethacin
Reactive arthritis HAART, SSZ, TNF- antagonists
Psoriasis HAART, MTX, TNF- antagonists
Gout HAART without stavudine and didanosine
Septic (intravenous drug abuse) Antimicrobial
Cryoglobulinaemia HAART, IFN and ribavirin in HCV coinfection
Myalgia Primary HIV infection Symptomatic
Some statins if given with some PI Switch statin and/or avoid PI
Rhabdomyolysis Primary HIV infection Symptomatic
Alcoholism, cocaine, other illicit drugs Avoid precipitating agent
Statins in the setting of PI cotherapy Replace
Trimethoprim/sulphamethoxazole Replace
Tenofovir-induced macroglobulinaemia Not a clinical problem
Muscle weakness Zidovudine myopathy Uridine supplement, avoid zidovudine
Polymyositis HAART
DILS HAART
Dermatomyositis Unknown
Nemaline rod myopathy Prednisolone? Plasmapheresis?
Wasting syndrome HAART
Pyomyositis Antimicrobial
Osteonecrosis Corticosteroids Symptomatic
PI controversial
Osteopenia/osteoporosis Multifactorial? Eliminate cofactors (smoking), vitamin D, calcium, biphosphonates
Osteomalacia Tenofovir-induced hypophosphataemia Replace tenofovir, phosphate supplementation
Osteomyelitis Staphylococcus aureus and other organisms Anti-microbial treatment
Vasculitis PAN HAART, treatment of HBV coinfection
Hypersensitivity vasculitis HAART, corticosteroids, immunosuppression
Cryoglobulinaemia HAART, IFN plus ribavirin in HCV coinfection
Behc¸et’s-like disease Unknown
Aneurysmatic or obstructive large-vessel vasculitis Rule out lues, treatment unknown
Cerebral vasculitis Unknown
Vasculitic manifestations due to lymphoma Chemotherapy
Infections (varicella zoster, CMV) Anti-viral
DILS Must be differentiated from SS, HCV,
Pneumocystis jirovecii pneumonia and sarcoidosis
HAART
Sarcoidosis Unknown Corticosteroids
Parotid lipomatosis Ritonavir Avoid ritonavir doses exceeding 200 mg/day
SLE Unknown HCQ, immunosuppression
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infection itself, urate serum levels are also altered by anti-
retrovirals [54]. Didanosine, for example, causes hyperuricaemia
[55] and urate measurements were even proposed as an index of
drug compliance [56]. In a recent multivariate cohort analysis,
hyperuricaemia was associated with factors previously identified
in HIV-uninfected individuals, but in addition with the use of
some anti-retrovirals, particularly with stavudine and didanosine
[54]. Urate elevation may result from the mitochondrial toxicity
of these drugs, because mitochondrial damage increases the
formation of lactate, which stimulates urate reabsorption at the
proximal tubulus of the kidney [57]. Mitochondrial failure also
causes ATP depletion that promotes urate production in the
purine nucleotide cycle [58].
Myopathy
Muscular complications associated with HIV consist of rhabdo-
myolysis, zidovudine myopathy [59–61], an HIV-associated
polymyositis [23, 62–67], dermatomyositis [68], inclusion body
myositis [69, 70], nemaline rod myopathy [66, 67], wasting
syndrome [71, 72] and pyomyositis [37, 38, 73, 74].
Rhabdomyolysis
Rhabdomyolysis may either complicate primary HIV infection
[75, 76], result from the use of the interaction between PI and
statins or be due to other drugs [77–79]. A hypersensitivity
reaction to abacavir, for example, has triggered rhabdomyolysis
[80]. Rhabdomyolysis and more frequently myalgia may be
induced in patients who receive lipid-lowering agents to counter-
act dyslipidaemia as a common side-effect of HAART. These
complications result from significantly elevated statin concentra-
tions in the serum due to the shared metabolism of statins and PI
at hepatic cytochrome P 450 isoenzymes [81–84]. Lovastatin and
simvastatin, in particular, should be avoided with PI co-treatment
and pravastatin considered the cholesterol-lowering agent of
choice [85]. Atorvastatin may also be used with caution but should
be used as a second-line agent [83, 85].
The formation of a macroenzyme CK has been observed in
approximately half of the patients treated with tenofovir [86].
Macro CK should be suspected with a disproportional elevated
MB isoenzyme activity and does not reflect a clinically significant
cardiac or skeletal myopathy.
Zidovudine
Zidovudine causes a myopathy by interfering with the replication
of mitochondrial DNA [59, 60]. The myopathy is probably
specific to zidovudine because it is generally not observed under
treatment with other anti-retroviral nucleoside analogues [60, 87].
Zidovudine myopathy is probably the most frequent muscle
complication in HIV patients and also more common than the
inherited mitochondrial myopathies due to mutations in the
mitochondrial genome [88]. Patients experience muscle weakness
either under dynamic or static exercise [89]. The serum CK is often
normal or only minimally elevated [89] but muscle histology
reveals a high frequency of ragged-red fibres in the Gomori
Trichrome stain. By histochemistry and electron microscopy a
high frequency of cytochrome c-oxidase negative fibres harbour-
ing abnormal mitochondria are found. Zidovudine myopathy may
be prevented by uridine supplementation and resolves within
months after drug cessation [60, 90].
HIV-associated polymyositis
This has been described in up to 2–7% of HIV-positive patients
and can be observed at any stage during the course of the infection
[5, 23, 62]. In a prospective trial of consecutive HIV-infected
patients untreated with anti-retrovirals but clinically suspected
skeletal myopathy or raised serum CK levels, one-third of the
cases had an inflammatory condition on skeletal muscle biopsy
(microvasculitis, myositis) [91]. The muscle is typically infiltrated
by CD8þ T-lymphocytes [65]. Viral antigen and nucleic acids have
been detected in endomysial lymphocytes [63, 64]. HIV-associated
polymyositis is clinically and histologically indistinguishable
from idiopathic polymyositis but mostly has a good outcome as
it responds well to immunosuppressive therapy and may even
resolve spontaneously [62]. About half of the patients simulta-
neously have a diffuse infiltrative lymphocytosis syndrome
(DILS) [62, 92].
Dermatomyositis and inclusion body myositis
Dermatomyositis [68] and inclusion body myositis were observed
with HIV infection only rarely [69, 70]. In inclusion body myositis,
HIV-specific CD8þ T cells appear to recognize antigens on the
surface of muscle fibres [70].
Nemaline rod myopathy
A nemaline rod myopathy of adult onset is also rare. Patients
progressively develop a painless muscle weakness and wasting
with elevated serum CK [66, 67]. Muscle biopsy discloses atrophic
type 1 fibres carrying numerous intracytoplasmic nemaline rod
bodies, whereas necrotic fibres and inflammatory infiltrates are
not features of the disease. Despite the absence of muscle inflam-
mation, some patients may respond to prednisolone or plasma-
pheresis, which suggests an autoimmune mechanism [93, 94].
Severe muscle atrophy may be caused by the AIDS-defining
‘wasting syndrome’ that is characterized by an involuntary weight
loss of at least 10% of body weight due to persistent diarrhoea,
weakness or fever without concurrent illness. Where anti-retroviral
treatment is available, wasting has become rare [71]. Muscle biopsy
usually reveals diffuse, or type II fibre atrophy, mild neurogenic
atrophy or thick filament loss without inflammation [72].
Pyomyositis
Pyomyositis is also a rare microbial infection, which mainly affects
male patients with low CD4þ counts [37]. Staphylococcus aureus is
the agent most frequently isolated [37, 38, 73, 74] but many other
organisms have also been identified.
Bone complications
Osteonecrosis
HIV-infected patients have an 100-fold elevated risk of
osteonecrosis compared with the general population. At the hip,
which is the most frequent localization of osteonecrosis, the
prevalence was estimated as 4.4% by MRI [95]. The annual
incidences were 0.7 and 0.3% with regard to asymptomatic and
symptomatic osteonecrosis of the femoral head [96]. Hip
osteonecrosis is frequently bilateral and may also be associated
with avascular necrosis of other bones. Eleven percent of initially
asymptomatic patients eventually require hip replacement [96].
Chronic inflammation, corticosteroids in the setting of immune
reconstitution and aCLs have been suggested as risk factor by
some but not all studies [95–99]. Osteonecrosis was attributed to
hypertriglyceridaemia secondary to PI treatment, but other studies
could not confirm the association of PI and osteonecrosis [95, 98].
Bone mineral loss
Osteopenia and osteoporosis are highly prevalent among
HIV-infected patients. The loss of bone minerals is of multi-
factorial origin [100]. HIV-mediated immune activation and
cytokine release contribute [101]. PI treatment was implicated
in cross-sectional studies [102] but later refuted in longitudinal
studies [101, 103]. It has been demonstrated that biphosphonates
increase bone mass density also in HIV-infected individuals
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[104, 105] but it is not known if HIV-associated osteopenia
actually increases the risk of bone fractures [106]. Thus, it is
unclear if fractures can be prevented by biphosphonates in the
setting of HIV infection.
Osteomalacia
Symptomatic osteomalacia due to tenofovir nephrotoxicity has
been described [107, 108]. Tenofovir probably inhibits the repli-
cation of mitochondrial DNA in the proximal tubules of the
kidney and through this mechanism induces a Fanconi syndrome
with tubular phosphate loss [109]. Osteomalacia should be sus-
pected with hypophosphatemia and elevated alkaline phospha-
tase. Skeletal scintigraphy may reveal pseudofractures (Looser’s
zones) that are not evident in routine radiographs. The symptoms
of osteomalacia improve during the course of a few weeks when
tenofovir is discontinued and the phosphate substituted.
Osteomyelitis
Bone infections tend to occur at lower CD4þ counts than joint
infections. Staphylococcus aureus is the most frequent pathogen
[37, 39, 110] but polymicrobial infections are observed in a con-
siderable proportion of HIV-associated osteomyelitis [110].
Multisystem manifestations
Vasculitis
A wide range of vasculitic manifestations were reported in HIV-
infected individuals. Vasculitis was described early in the disease
with CD4 counts >500/l, and in severe immune-compromised
patients with CD4 counts <200/l [111]. Vascular inflammation
was looked for in 148 muscle, nerve or skin biopsies of
symptomatic HIV-infected patients and found in 34 subjects
[112]. Using the ACR 1990 classification criteria, four patients
were classified as having PAN, one as having HSP and six as
having drug-induced hypersensitivity vasculitis [112]. The majority
of patients, however, had unspecific neutrophilic or monocytic
vascular inflammation and heterogenous clinical features that
included cutaneous rash, peripheral neuropathy or both [112].
Cryoglobulins (types II and III) were found in 1–27% of HIV-
monoinfected, but far more frequently in HIV/HCV-co-infected
patients [113–116]. Cryoglobulinaemic individuals appear to have
lower C3 levels than their cryoglobulin-negative counterparts, but
an association with HIV-viral load and CD4þ count is not evident
[114–116]. Symptomatic cryoglobulinaemia may present with
palpable purpura, mononeuritis, multiplex, arthralgias and
nephrotic range proteinuria [115, 117], but in the majority of
HIV-monoinfected patients, cryoglobulinaemia remains asympto-
matic [114, 116, 118]. The prevalence of cryoglobulinaemia among
HIV-positive/HCV-negative patients declines in the HAART era
[119]. In the setting of HIV/HCV-co-infection, sustained clinical
remission of cryoglobulinaemia can usually be achieved with IFN
and ribavirin [117].
Among the vasculitides affecting the medium-sized arteries,
cases of HIV-associated polyarteritis nodosa were observed
[112, 120]. HIV antigens and HIV RNA were observed in the
vessels in the absence of hepatitis B surface antigen [112, 120].
Behc¸et’s disease has been described sporadically in HIV-infected
patients [121]. A recent report from a tertiary hospital in China
pointed out that 15% of HIV-infected patients had a Behc¸et’s-
like disease, defined with at least three of the following features:
oral and genital ulcerations recurring at least three times in a
12-month period, typical eye and skin lesions and a negative
pathergy test [8].
Vasculitic complications of larger arteries in HIV-infected
patients include coronaritis [122] and a large-vessel vasculitis with
multiple aneurysms in African patients [123]. While some patients
with occlusive or aneurysmatic large vessel involvement have an
infectious cause, others have a leucocytoclastic vasculitis of the
vasa vasora and periadventitial vessels [124, 125].
Among HIV-infected patients with stroke, vasculitis was identi-
fied as the cause in 13% of individuals [126]. Cerebral vasculitis
can occur immediately after HIV infection or in more advanced
disease with CD4 counts <200/l [127, 128]. Granulomatous
angiitis of the central nervous system (CNS) was found to even
precede HIV seroconversion [129]. This condition is not specific to
HIV and can be seen when the immune system is compromised for
any reason [124]. It should, however, be borne in mind that CNS
vasculitis with HIV infection may also be triggered by opportu-
nistic infections with varicella zoster or CMV or be due to
lymphoma [127]. Granulomatous necrotizing vasculitis was also
observed outside the CNS in one case and then found to respond
to anti-retroviral treatment [130].
DILS
DILS is a common problem in HIV-infected patients; the
prevalence of DILS in this population is 3% [131]. DILS may
be confused with SS because DILS also presents with bilateral
painless parotid gland enlargement, lacrimal gland enlargement
and sicca symptoms [131]. DILS is characterized by circulating
CD8þ lymphocytosis and antigen-driven CD8þ T cell infiltration
of multiple organs. The condition usually manifests several years
after HIV-seroconversion and is thought to reflect an excessive
host response to HIV [132, 133]. Extraglandular complications
consist of lymphoid interstitial pneumonitis (31%), muscular
(26%) and hepatic (23%) involvement [62, 134]. Muscle mani-
festations are indistinguishable from polymyositis [92, 134]. A
disproportionately greater degree of salivary gland enlargement
and extraglandular disease, the low frequency of autoantibodies
and RF, and the association with HLA-DR5 and -DRB1
distinguish DILS from SS [133, 135]. Anti-retroviral therapy is
effective and probably also accounts for the declining incidence of
DILS in the HAART era [135].
Parotid lipomatosis, a parotid gland swelling due to abnormal
fat deposition was associated with PI therapy [136] and may
represent a metabolic complication of high doses of ritonavir.
These doses are no longer applied today. Gallium scans may
distinguish parotid lipomatosis from DILS, the latter featuring an
intense, bilateral salivary gland gallium uptake [137].
Sarcoidosis
The association of HIV and sarcoidosis was considered rare
because CD4þ lymphocytes appear to play an important role in
granuloma formation [138, 139]. In only few patients, sarcoidosis
occurred in the absence of HAART [140, 141]. Although HIV-
negative patients with sarcoidosis have also a decrease in
peripheral blood T lymphocytes, a phenomenon which can be
explained at least in part by the recruitment of T lymphocytes
from the blood to the site of active granuloma formation, most
patients with symptomatic sarcoidosis in the context of HIV
infection had peripheral CD4þ lymphocyte counts >200l [142].
Sarcoidosis is now mostly observed in patients with marked
increases in CD4þ cell counts under HAART [9, 138, 140]. In the
setting of such immune reconstitution, the interval between the
introduction of HAART and the onset of pulmonary sarcoidosis
was longer (several months) than that reported for granuloma
formation secondary to infections (a few weeks) [140, 143].
Infections with pneumocystis jirovecii, cryptococcus, toxoplasma,
CMV and mycobacteria must be excluded. In the HAART era,
most patients with sarcoidosis showed improvement with immu-
nosuppression and one with discontinuation of HAART [141].
SLE
SLE generally improves during the course of untreated HIV
infection, which is consistent with the importance of CD4þ T cells
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in the pathogenesis of SLE [144, 145]. Conversely, inactive pre-
existing SLE can flare with immune recovery under HAART
[9, 146]. Difficulties in the differential diagnosis between SLE and
HIV infection may arise, because there are many clinical and
laboratory similarities. For example, oral ulcerations, sicca
syndrome, alopecia, arthritis, fever and neuropathies can be
features of both conditions. Similarly, both entities can be
accompanied by leucopenia, lymphopenia, thrombopenia, hyper-
gammaglobulinaemia, ANA and the presence of aPLs [13, 147,
148]. Anti-dsDNA antibodies, are considered by some but not all
investigators to be specific for SLE [12, 148]. Anti-HIV antibody
tests can be falsely positive in SLE because sera from SLE patients
contain antibodies that interact with HIV in western blot analyses
[149–151]. Thus, positive HIV-antibody tests should be confirmed
by antigen or nucleic acid detection in the setting of a CTD. It has
also been described that the HIV infection emerged and took a
rapidly progressive course after immunosuppressive therapy was
initiated in order to treat SLE [147]. For this reason, it strongly
recommended that subjects with SLE be tested for HIV prior to
the commencement of immunosuppressive treatment.
Anti-rheumatics in HIV-infected individuals
For symptomatic relief of musculoskeletal symptoms, NSAIDs
can be used according to the guidelines in HIV-negative patients.
Interestingly, indomethacin has been shown to inhibit HIV
replication in vitro, with the dose for 50% inhibition of viral
replication corresponding to 50mg of indomethacin [152].
Indomethacin may, therefore, be the NSAID to be preferentially
considered in HIV patients. SSZ has been used successfully in
SpAs not sufficiently responding to NSAIDs and does not
adversely promote HIV replication [153, 154]. Although MTX
was initially viewed as contraindicated in the setting of HIV
infection because of its immunosuppressive mechanism of action,
MTX may be used with careful monitoring of HIV viral loads and
CD4 counts [155, 156]. HCQ has been effectively used in HIV-
associated arthropathies [157]. Moreover, HCQ has anti-retroviral
activity [158]. In a dose of 800mg/day, HCQ was equal to
zidovudine in controlling viral replication in HIV-infected patients
[159, 160]. The anti-retroviral effect of HCQ was, however, only
investigated for a daily dose of 800mg of HCQ, a dose that is far
more than the dose usually used to treat arthritis.
SpAs not responding to conventional DMARDs may require
TNF- blockade. Exogenous TNF- was found to enhance HIV
replication in a number of cell lines, which indicates that anti
TNF- biologics may have a beneficial effect on the course of HIV
infection [161]. Such anti-retroviral action of TNF- antagonists
has, however, not been confirmed clinically; two consecutive
infusions of infliximab were, however, well tolerated in six HIV
patients with CD4þ counts <200/l [162]. Good responses
without severe side-effects were reported in cases of Reiter’s
syndrome, PsA and AS [31, 33, 163]. In some patients, however,
the TNF- agent had to be stopped despite efficacy due to
intercurrent infections [34]. In a recent series of eight HIV patients
treated with infliximab, etanercept or adalimumab, no deteriora-
tion due to HIV disease was observed during a mean observa-
tion period of 28 months [163]. Anti-TNF- agents may also be
safely used in the setting of hepatitis B and C virus coinfection
[164, 165].
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